Prediction: Johnson & Johnson Will Be a Faster-Growing Company by 2030 Than Most Investors Expect
Don't underestimate this healthcare giant.
Overview
Johnson & Johnson (NYSE: JNJ) has many qualities. It is one of the largest healthcare companies in the world and boasts an incredibly diversified business and an AAA rating from S&P Global, the highest rating available. However, whatever one might say about Johnson & Johnson, the company is hardly a good pick for growth-oriented investors. Still, the drugmaker may improve sales and earnings growth over the next few years, and by 2030, it may be growing faster than many expect. Here is why.
Image source: The Motley Fool.
Johnson & Johnson is a diversified healthcare player, but it used to be even more so. The company had a consumer health business through which it offered various over-the-counter healthcare products. Many of them were fairly well-known brands. However, this was a mature business that typically grew its sales more slowly than Johnson & Johnson's two other segments: biopharma and medtech.
Details
Source
Originally published at www.fool.com.